FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 805 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Removing senescent immune cells could be the key to preventing some... June 1, 2023 Adjuvant Therapy with Oxaliplatin Added to Fluoropyrimidine Improves Survival in Patients... January 15, 2021 Plans for NCI’s Fiscal Year 2019 Budget December 18, 2018 El cáncer en mi comunidad: Ampliar el acceso a las pruebas... September 1, 2020 Load more HOT NEWS FDA Approves Cemiplimab-rwlc for Advanced Non-Small Cell Lung Cancer With High... Higher Rates of Metastasis-Free Survival in Men with High-Risk Non-Metastatic Prostate... Improving research with registered reports Leading Change in Cancer Clinical Research, Because Our Patients Can’t Wait
